One of the offerings is a myeloid panel that can detect abnormalities in 70 genes associated with a range of diseases, including acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. The panel can detect clinically relevant single nucleotide variants and insertion-deletion mutations (indels) with a 1% variant allele frequency, according to the company.
“One of the key facets of our SureSeq NGS panel offering is our customisation programme, SureSeq myPanel, in this we collaborate with our customers to rapidly generate the content that they desire, often this is at the forefront of discovery and not always commercially available,” said Emma Shipstone, executive vice president marketing at OGT. “Once there is community consensus on desired content we have the ability to bring panel content previously developed and optimized to a broader market.”
In addition, a 7-gene breast and ovarian cancer panel targets genes commonly tied to breast and ovarian cancer, such as BRCA1 and BRCA2. The panel also can detect copy number variation, the disparity in the number of copies of genes among individuals tied to several cancers, OGT said. The full interrogation of BRCA genes conventionally has required multiple tests to identify indels, single nucleotide variants and copy number variations. The SureSeq breast cancer panel can identify such variations in a single test, according to the manufacturer.
The breast and ovarian cancer panel also may identify mutations related to ataxia-telangiectasia mutated (ATM) genes, tumor protein P53, checkpoint kinase 2 (CHEK2), partner and localizer of BRCA2 (PALB2) in addition to phosphatase and tensin homolog (PTEN). The panel can also detect copy number variations in single exons in addition to full gene deletions or duplications in these genes, the company said.